142 related articles for article (PubMed ID: 11481622)
1. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine.
Young MD; Schneider DL; Zuckerman AJ; Du W; Dickson B; Maddrey WC;
Hepatology; 2001 Aug; 34(2):372-6. PubMed ID: 11481622
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.
Young MD; Gooch WM; Zuckerman AJ; Du W; Dickson B; Maddrey WC
J Med Virol; 2001 Jul; 64(3):290-8. PubMed ID: 11424117
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines.
Zuckerman JN; Zuckerman AJ; Symington I; Du W; Williams A; Dickson B; Young MD;
Hepatology; 2001 Oct; 34(4 Pt 1):798-802. PubMed ID: 11584378
[TBL] [Abstract][Full Text] [Related]
4. Recombinant hepatitis B triple antigen vaccine: Hepacare.
Zuckerman JN; Zuckerman AJ
Expert Rev Vaccines; 2002 Aug; 1(2):141-4. PubMed ID: 12901552
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
Raz R; Koren R; Bass D
Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
[TBL] [Abstract][Full Text] [Related]
6. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule.
Connor BA; Blatter MM; Beran J; Zou B; Trofa AF
J Travel Med; 2007; 14(1):9-15. PubMed ID: 17241248
[TBL] [Abstract][Full Text] [Related]
7. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
Van Damme P; Leroux-Roels G; Law B; Diaz-Mitoma F; Desombere I; Collard F; Tornieporth N; Van Herck K
J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
9. A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine.
Young MD; Rosenthal MH; Dickson B; Du W; Maddrey WC
Vaccine; 2001 May; 19(25-26):3437-43. PubMed ID: 11348708
[TBL] [Abstract][Full Text] [Related]
10. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine.
André FE; Safary A
Postgrad Med J; 1987; 63 Suppl 2():169-77. PubMed ID: 3317357
[TBL] [Abstract][Full Text] [Related]
11. [Humoral immunity level and factors associated with the response to the vaccine against the hepatitis B virus in health personnel of the Case-Essalud National Hospital, Arequipa September 1995-March 2002].
Campos Nizama J
Rev Gastroenterol Peru; 2005; 25(2):141-9. PubMed ID: 16021199
[TBL] [Abstract][Full Text] [Related]
12. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth.
Jafarzadeh A; Montazerifar SJ
J Ayub Med Coll Abbottabad; 2006; 18(4):4-9. PubMed ID: 17591001
[TBL] [Abstract][Full Text] [Related]
13. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of yeast-derived hepatitis B vaccines in young adults.
Bergamini F; Zanetti A
Postgrad Med J; 1987; 63 Suppl 2():137-8. PubMed ID: 3317349
[TBL] [Abstract][Full Text] [Related]
15. Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene) in healthy adults.
Rebedea I; Diaconescu IG; Bach D; Bartelsen O; Arndtz N
Vaccine; 2006 Jun; 24(25):5320-6. PubMed ID: 16707195
[TBL] [Abstract][Full Text] [Related]
16. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
Jafarzadeh A; Zarei S; Shokri F
Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of vaccination against hepatitis B in adult with HIV infection].
Kalinowska-Nowak A; Bociaga-Jasik M; Garlicki A; Mach T
Przegl Epidemiol; 2007; 61(2):339-47. PubMed ID: 17956052
[TBL] [Abstract][Full Text] [Related]
19. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
[TBL] [Abstract][Full Text] [Related]
20. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
